| P/E (FY) | — | Sales (TTM) | $151.4M |
| Earnings (TTM) | -$312.8M | ROE | −51.08% |
| Net Margin | −183.81% | ROIC | −100.46% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −29.11% |
| Market Cap | $427.0M | Trading Days | 1207 |
| 52W High | 17.58 |
| 52W Low | 5.37 |
| % Off High | −56.20% |
| YTD | −7.34% | 1Y | −44.84% |
| 3Y | −92.11% | Since incept. (ann.) | −57.13% |
Cell Engineering 100%
| Ann. Volatility (1Y) | 94.14% | Ann. Volatility (3Y) | 99.93% |
| Sharpe (1Y) | −0.18 | Sharpe (3Y) | −0.33 |
| Max Drawdown (1Y) | −66.05% | Max Drawdown (3Y) | −94.66% |
| Beta (3Y, vs SPY) | 2.59 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| OCGN | Ocugen, Inc. | $419.8M | — |
| CABA | Cabaletta Bio, Inc. | $445.1M | — |
| REPL | Replimune Group, Inc. | $449.1M | — |
| KYTX | Kyverna Therapeutics, Inc. | $455.4M | — |
| STRO | SUTRO BIOPHARMA, INC. | $393.2M | — |
| CCCC | C4 Therapeutics, Inc. | $392.5M | — |
| AUTL | Autolus Therapeutics plc | $385.9M | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $490.3M | — |
| XFOR | X4 Pharmaceuticals, Inc | $370.7M | — |
| IPSC | Century Therapeutics, Inc. | $369.7M | — |
| RGNX | REGENXBIO Inc. | $496.3M |
| — |
| CMPX | Compass Therapeutics, Inc. | $367.4M | — |
